Hear from Verve, Biogen, Entrada Tx on oligonucleotide development
The oligonucleotide industry needs collaboration between biopharma and regulatory experts to optimize manufacturing processes, develop robust analytical methods, and ensure the quality and safety of oligonucleotide-based therapeutics.
This August, the oligonucleotide field will join forces at the Oligonucleotide CMC & Analytical Development Summit, to unlock the potential of oligonucleotides beyond rare disease to treat large patient populations for undruggable targets.
Industry leaders will share thought-leadership focused on improving analytical characterization and effectively preparing CMC data for IND filing and scale up, here’s a snapshot of what you can expect to hear in August:
- Mahir Ozdemire, Associate Director at Johnson & Johnson will showcase examples of J&J’s activities in separating oligonucleotide impurities to help you in leveraging your platform processes for accurate measurements
- Sibo Jiang, Head of CMC, SanegeneBio will help you to navigate early CMC development challenges with late stage readiness in mind for commercial success
- Carlo Zambonelli, Senior Director at Verve Therapeutics will discuss methods of outlining gRNA purity, their limits and understanding that not all impurities are created equal
- Raj Pandey, VP at Cargene Therapeutics is running an interactive workshop to help support brainstorming on developing high quality oligonucleotide conjugates, outlining the additional CMC considerations to develop your knowledge of complex oligonucleotide development
For the full scope of this year’s meeting, including the expert speaker faculty and the full agenda packed with industry-led sessions, take a look at the event brochure here.
With the market sky-rocketing and pipelines developing, this is your chance to be at the cutting edge.
To view your registration options, click here. Don’t forget to take advantage of early bird and group booking discounts!